LONDON (Alliance News) - Scancell Holdings PLC on Monday said it appointed two new executives as head of research and head of manufacturing.
Samantha Paston joined Scancell as head of research in mid-January. She came from Immunocore where she has held several positions since June 2008.
"While at Immunocore Samantha was responsible for the generation of the in house T cell cloning method and biological molecule discovery which made significant contributions to the current Immunocore oncology pipeline," Scancell, which focuses on developing immunotherapies for cancer treatment, said.
Furthermore, Scancell appointed Adrian Parry as head of manufacturing. Parry will join the firm at the beginning of February after leaving his role at Mereo BioPharma PLC.
Scancell Chief Executive Cliff Holloway said: "We are delighted to welcome both Samantha and Adrian to Scancell. Samantha's experience in T cell cloning and working with biological molecules, from drug discovery through to early development, will be invaluable as we continue to progress our pipeline of cancer immunotherapies. Likewise, Adrian's 20 years of CMC (chemistry, manufacturing and controls) and GMP development expertise will be key for our manufacturing capabilities moving forward."
Scancell shares were trading up 4.0% at 8.42 pence each.